Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous tranexamic acid for blood loss reduction in posterior lumbar interbody fusion
ChiCTR1900025176Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tranexamic acid in lumbar spinal stenosis (LSS), Herniated Lumbar Disk and lumbar spondylolisthesis (3 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: blood loss, postoperative drainage and 2 more. Started Aug 2019; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
lumbar spinal stenosis (LSS)Herniated Lumbar Disklumbar spondylolisthesis
Beyond the preview
Go deeper on ChiCTR1900025176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025176.